K.J. Harrison & Partners Inc Makes New $2.26 Million Investment in Danaher Co. (NYSE:DHR)

K.J. Harrison & Partners Inc bought a new position in Danaher Co. (NYSE:DHR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 9,786 shares of the conglomerate’s stock, valued at approximately $2,264,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. GHP Investment Advisors Inc. lifted its holdings in shares of Danaher by 540.0% in the third quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock valued at $40,000 after purchasing an additional 135 shares in the last quarter. Meridian Wealth Management LLC boosted its position in Danaher by 99.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 3,264 shares of the conglomerate’s stock worth $810,000 after acquiring an additional 1,628 shares during the period. Koshinski Asset Management Inc. boosted its position in Danaher by 16.2% during the 3rd quarter. Koshinski Asset Management Inc. now owns 1,118 shares of the conglomerate’s stock worth $277,000 after acquiring an additional 156 shares during the period. Asset Management One Co. Ltd. grew its stake in Danaher by 0.3% during the 3rd quarter. Asset Management One Co. Ltd. now owns 324,221 shares of the conglomerate’s stock valued at $80,439,000 after acquiring an additional 1,051 shares in the last quarter. Finally, Ballast Advisors LLC acquired a new position in shares of Danaher in the 3rd quarter valued at about $485,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on DHR shares. Barclays boosted their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Robert W. Baird increased their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday. Bank of America boosted their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, TD Cowen raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Stock Performance

Shares of DHR stock traded up $0.65 during trading hours on Friday, reaching $246.45. 2,710,445 shares of the company’s stock were exchanged, compared to its average volume of 2,785,746. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $182.54 billion, a P/E ratio of 41.77, a P/E/G ratio of 4.19 and a beta of 0.83. The business has a fifty day moving average price of $248.87 and a 200-day moving average price of $231.08.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period last year, the business earned $2.36 earnings per share. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. Analysts predict that Danaher Co. will post 7.64 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Activity

In related news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 106,565 shares of company stock worth $26,641,364. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.